vs

Side-by-side financial comparison of LANDS' END, INC. (LE) and Sarepta Therapeutics, Inc. (SRPT). Click either name above to swap in a different company.

Sarepta Therapeutics, Inc. is the larger business by last-quarter revenue ($369.6M vs $317.5M, roughly 1.2× LANDS' END, INC.). LANDS' END, INC. runs the higher net margin — 1.6% vs -111.5%, a 113.2% gap on every dollar of revenue. On growth, LANDS' END, INC. posted the faster year-over-year revenue change (0.1% vs -42.1%). Sarepta Therapeutics, Inc. produced more free cash flow last quarter ($127.6M vs $-22.4M). Over the past eight quarters, Sarepta Therapeutics, Inc.'s revenue compounded faster (1.4% CAGR vs -0.9%).

Lands' End, Inc. is an American retailer of clothing, baggage, and furniture which began as a mail-order yachting supply company in 1963 in Chicago. The company is named after Land's End; after promotional materials were printed, the founder noticed the typographical error in the location of the apostrophe, but could not afford to reprint the material. The company operates 26 domestic stores as of February 2024. Lands' End is headquartered in Dodgeville, Wisconsin.

Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of 2023, the company has four approved drugs.

LE vs SRPT — Head-to-Head

Bigger by revenue
SRPT
SRPT
1.2× larger
SRPT
$369.6M
$317.5M
LE
Growing faster (revenue YoY)
LE
LE
+42.2% gap
LE
0.1%
-42.1%
SRPT
Higher net margin
LE
LE
113.2% more per $
LE
1.6%
-111.5%
SRPT
More free cash flow
SRPT
SRPT
$150.0M more FCF
SRPT
$127.6M
$-22.4M
LE
Faster 2-yr revenue CAGR
SRPT
SRPT
Annualised
SRPT
1.4%
-0.9%
LE

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
LE
LE
SRPT
SRPT
Revenue
$317.5M
$369.6M
Net Profit
$5.2M
$-412.2M
Gross Margin
51.8%
Operating Margin
5.3%
-111.4%
Net Margin
1.6%
-111.5%
Revenue YoY
0.1%
-42.1%
Net Profit YoY
198.3%
-359.2%
EPS (diluted)
$0.17
$-3.92

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LE
LE
SRPT
SRPT
Q4 25
$317.5M
$369.6M
Q3 25
$370.0M
Q2 25
$261.2M
$513.1M
Q1 25
$611.5M
Q4 24
$318.6M
$638.2M
Q3 24
$317.2M
$429.8M
Q2 24
$285.5M
$360.5M
Q1 24
$514.9M
$359.5M
Net Profit
LE
LE
SRPT
SRPT
Q4 25
$5.2M
$-412.2M
Q3 25
$-50.6M
Q2 25
$-8.3M
$196.9M
Q1 25
$-447.5M
Q4 24
$-593.0K
$159.0M
Q3 24
$-5.3M
$33.6M
Q2 24
$-6.4M
$6.5M
Q1 24
$-8.6M
$36.1M
Gross Margin
LE
LE
SRPT
SRPT
Q4 25
51.8%
Q3 25
59.3%
Q2 25
50.8%
70.3%
Q1 25
77.5%
Q4 24
50.6%
Q3 24
47.9%
78.7%
Q2 24
48.7%
87.6%
Q1 24
38.0%
85.9%
Operating Margin
LE
LE
SRPT
SRPT
Q4 25
5.3%
-111.4%
Q3 25
-27.9%
Q2 25
-0.9%
22.5%
Q1 25
-49.1%
Q4 24
2.9%
25.3%
Q3 24
0.8%
5.2%
Q2 24
0.8%
-0.2%
Q1 24
1.6%
9.7%
Net Margin
LE
LE
SRPT
SRPT
Q4 25
1.6%
-111.5%
Q3 25
-13.7%
Q2 25
-3.2%
38.4%
Q1 25
-73.2%
Q4 24
-0.2%
24.9%
Q3 24
-1.7%
7.8%
Q2 24
-2.3%
1.8%
Q1 24
-1.7%
10.0%
EPS (diluted)
LE
LE
SRPT
SRPT
Q4 25
$0.17
$-3.92
Q3 25
$-0.50
Q2 25
$-0.27
$1.89
Q1 25
$-4.60
Q4 24
$-0.02
$1.56
Q3 24
$-0.17
$0.34
Q2 24
$-0.20
$0.07
Q1 24
$-0.27
$0.37

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LE
LE
SRPT
SRPT
Cash + ST InvestmentsLiquidity on hand
$36.3M
$939.6M
Total DebtLower is stronger
$829.0M
Stockholders' EquityBook value
$231.0M
$1.1B
Total Assets
$852.7M
$3.3B
Debt / EquityLower = less leverage
0.73×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LE
LE
SRPT
SRPT
Q4 25
$36.3M
$939.6M
Q3 25
$851.0M
Q2 25
$18.1M
$800.1M
Q1 25
$522.8M
Q4 24
$30.4M
$1.4B
Q3 24
$25.6M
$1.2B
Q2 24
$27.4M
$1.5B
Q1 24
$25.3M
$1.4B
Total Debt
LE
LE
SRPT
SRPT
Q4 25
$829.0M
Q3 25
$140.5M
Q2 25
Q1 25
Q4 24
$1.1B
Q3 24
$1.2B
Q2 24
$1.2B
Q1 24
$1.2B
Stockholders' Equity
LE
LE
SRPT
SRPT
Q4 25
$231.0M
$1.1B
Q3 25
$1.3B
Q2 25
$230.1M
$1.4B
Q1 25
$1.1B
Q4 24
$223.6M
$1.5B
Q3 24
$226.5M
$1.2B
Q2 24
$234.6M
$1.1B
Q1 24
$241.6M
$961.2M
Total Assets
LE
LE
SRPT
SRPT
Q4 25
$852.7M
$3.3B
Q3 25
$3.5B
Q2 25
$760.5M
$3.7B
Q1 25
$3.5B
Q4 24
$843.6M
$4.0B
Q3 24
$802.5M
$3.6B
Q2 24
$800.1M
$3.4B
Q1 24
$811.5M
$3.2B
Debt / Equity
LE
LE
SRPT
SRPT
Q4 25
0.73×
Q3 25
0.11×
Q2 25
Q1 25
Q4 24
0.74×
Q3 24
1.01×
Q2 24
1.14×
Q1 24
1.29×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LE
LE
SRPT
SRPT
Operating Cash FlowLast quarter
$-15.7M
$131.2M
Free Cash FlowOCF − Capex
$-22.4M
$127.6M
FCF MarginFCF / Revenue
-7.1%
34.5%
Capex IntensityCapex / Revenue
2.1%
1.0%
Cash ConversionOCF / Net Profit
-3.03×
TTM Free Cash FlowTrailing 4 quarters
$-55.0M
$-307.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LE
LE
SRPT
SRPT
Q4 25
$-15.7M
$131.2M
Q3 25
$-14.6M
Q2 25
$-22.5M
$261.3M
Q1 25
$-583.4M
Q4 24
$-17.1M
$92.0M
Q3 24
$30.7M
$-70.7M
Q2 24
$-25.8M
$14.9M
Q1 24
$93.9M
$-242.1M
Free Cash Flow
LE
LE
SRPT
SRPT
Q4 25
$-22.4M
$127.6M
Q3 25
$-37.5M
Q2 25
$-30.7M
$229.5M
Q1 25
$-627.1M
Q4 24
$-27.8M
$54.0M
Q3 24
$26.0M
$-108.0M
Q2 24
$-32.6M
$-14.2M
Q1 24
$87.5M
$-274.5M
FCF Margin
LE
LE
SRPT
SRPT
Q4 25
-7.1%
34.5%
Q3 25
-10.1%
Q2 25
-11.8%
44.7%
Q1 25
-102.5%
Q4 24
-8.7%
8.5%
Q3 24
8.2%
-25.1%
Q2 24
-11.4%
-3.9%
Q1 24
17.0%
-76.4%
Capex Intensity
LE
LE
SRPT
SRPT
Q4 25
2.1%
1.0%
Q3 25
6.2%
Q2 25
3.2%
6.2%
Q1 25
7.1%
Q4 24
3.3%
6.0%
Q3 24
1.5%
8.7%
Q2 24
2.4%
8.1%
Q1 24
1.2%
9.0%
Cash Conversion
LE
LE
SRPT
SRPT
Q4 25
-3.03×
Q3 25
Q2 25
1.33×
Q1 25
Q4 24
0.58×
Q3 24
-2.10×
Q2 24
2.31×
Q1 24
-6.70×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LE
LE

U Se Commerce$179.8M57%
Business Outfitters Revenue$78.8M25%
Licensing And Retail$20.2M6%
Other$19.8M6%
Third Party$18.9M6%

SRPT
SRPT

Pmo Products$202.5M55%
Elevidys$110.4M30%
Other$56.7M15%

Related Comparisons